Daniel Gliddon

FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity

Matthew Kraman, Mustapha Faroudi, Natalie L. Allen et al. · Clinical Cancer Research · 2020 · 110 citations

Pharmacy, Immunology, Oncology +17

DEC‐205 expression on migrating dendritic cells in afferent lymph

Daniel Gliddon, Jayne C. Hope, Gareth P. Brooke et al. · Immunology · 2004 · 69 citations · Full text

Life Sciences, Immunology, Molecular Biology +12

FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models

Matthew A. Lakins, Alexander Koers, Raffaella Giambalvo et al. · Clinical Cancer Research · 2020 · 65 citations

Medicine, Oncology, Pharmacology +17

CD26 is expressed on a restricted subpopulation of dendritic cells in vivo

Daniel Gliddon, Chris J. Howard · European Journal of Immunology · 2002 · 52 citations · Full text

Life Sciences, Cell Biology, Immunology +17

A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance

Timothy A. Yap, Patricia LoRusso, Deborah J. Wong et al. · Clinical Cancer Research · 2022 · 50 citations · Full text

Pharmacy, Oncology, Pharmacology +17